

Condensed-Purines Syntheses of Tetrahydro-1,4-diazepino[1,2,3-*gh*]purin-2-one and Hexahydro-1,4-diazocino[1,2,3-*gh*]purin-2-one

Hirokazu SUZUKI,^{*,a} Hiroyuki SAWANISHI,^a Kenji YAMAMOTO,^b and Ken-ichi MIYAMOTO^c

Department of Synthetic Chemistry^a and Department of Chemistry,^b Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa machi, Kanazawa 920-1181, Japan, and Faculty of Pharmaceutical Science,^c Kanazawa University, Takara-machi, Kanazawa 920-0934, Japan. Received April 19, 1999; accepted June 25, 1999

1,4-Pyrimido- (2a), 1,4-diazepino- (2b), and 1,4-diazocino[1,2,3-*gh*]purine (2c) were designed as selective cAMP-phosphodiesterase 4 (PDE 4) inhibitors. The desired condensed-purines (2b,c) were synthesized by reaction of 7-aminoalkyl-3-propylpurine-2,4-diones (6b,c) with hexamethyldisilazane by intramolecular cyclization via silylation-amination.

Key words 1,4-diazepino[1,2,3-*gh*]purine; 1,4-diazocino[1,2,3-*gh*]purine; condensed-purine; silylation-amination; intramolecular cyclization

Inhibitors of cAMP-phosphodiesterase 4 (PDE 4) exhibit a range of anti-inflammatory/immunosuppressive activities which suggest potential in a wide range of inflammatory and autoimmune diseases.¹⁾ Most interest to date has centered on clinical evaluation in asthmatic patients.

On the basis of our studies on the structure-activity relationships of alkylxanthine for PDE 4 isoenzyme inhibitors,²⁾ we proposed that the interaction between the alkyl group at the 1-position and the oxo group at the 2- or 6-position of the xanthine skeleton was important for these activities, and we discovered the heterocycle[*i*]-condensed purine, 3,4-dipropyl-4,5,7,8-tetrahydro-3*H*-imidazo[1,2-*i*]purin-5-one (**1**) which showed selective PDE 4-inhibitory activity and lacked some of the adverse reactions of xanthine derivatives.³⁾ We thought that both the heterocycle-ring fused onto the purine ring and the conversion from a xanthine to a isoguanine skeleton might be important to elicit these activities. On the other hand, in our previous report,²⁾ alkyl substitution at the 7-position of the xanthine skeleton increased PDE 1-inhibitory activity and decreased PDE 3-inhibitory activity, without changing the PDE 4-inhibitory activity. In this study, we then designed the novel heterocycle[*g,h*]condensed-purines, 1,4-pyrimido- (**2a**) 1,4-diazepino- (**2b**), and 1,4-diazocino[1,2,3-*gh*]condensed-purine (**2c**). In present paper we describe the synthesis of these condensed-purines **2**.

We planned at first the synthesis of [*g,h*]condensed-

purines **2** by intramolecular cyclization of 7-aminoalkyl-3-propylpurine-2,4-dione (**6**) with phosphorus oxychloride, according to the method of Glushkov.⁴⁾ Treatment of enprofylline (**3**)⁵⁾ with the respective (*N*-benzyloxycarbonyl)-aminoalkyl methanesulfonate (**4**) in the presence of potassium carbonate gave the corresponding [7-(*N*-benzyloxycarbonyl)aminoalkyl]-3-propylpurine-2,4-diones (**5a,b,c**) in 68–86% yields. Removal of the benzyloxycarbonyl group of **5a,b,c** by catalytic hydrogenation with 20% palladium hydroxide on carbon gave 7-aminoalkyl-3-propylpurine-2,4-diones (**6a,b,c**). Although Glushkov obtained [*g,h*]condensed-purines (**9a,b**) from the reaction of 7-(dialkylamino)-3-methylpurine-2,4-diones (**8a,b**) with phosphorus oxychloride, we could not obtain the desired condensed-purines **2** from **6** under the same conditions because the intermediate (**7**) degraded during the chlorination-amination




Chart 1




Chart 2

* To whom correspondence should be addressed.




Chart 3

reaction (Chart 2).

Vorbrüggen reported that silylation-amination of inosine with hexamethyldisilazane (HMDS) and amine in the presence of a catalyst gave the corresponding adenosines in high yields.⁶⁾ However, intramolecular cyclization *via* silylation-amination with HMDS has not been reported previously. Therefore, intramolecular cyclization *via* silylation-amination was examined as a means of synthesizing **2**. Compound **6** was treated with HMDS in the presence of ammonium sulfate or trimethylchlorosilane as catalyst in pyridine at 140 °C. As a result, the desired condensed-purine **2b, c** ($n=3, 4$) were obtained from **6b, c** in 46% and 70% yields, respectively. This reaction involves silylation of the oxo group at the 6-position and amino group, followed by replacement reaction between trimethylsilanol and the amino group in one-pot. However, the same reaction of **6a** ($n=2$) led to **11** *via* dimerization of the intermediate **10a** because the alkyl chain of **10a** might be too short to allow the intramolecular cyclization. The structures of **2b, c** and **11** were assigned on the basis of ¹H-NMR and mass spectral data. For example, the ¹H-NMR spectrum of **2b** showed signals at 0.90, 1.81 and 4.07 ppm assignable to the propyl group, and at 2.30, 3.94 and 4.31 ppm assignable to the methylene group of the 1,4-diazepine ring, and at 7.64 and 10.57 ppm indicating aromatic and NH protons, respectively. The mass spectra (MS) of **2b, c** showed peaks at m/z 233 (M^+) and 247 (M^+), respectively, however that of **11** showed a peak at m/z 438 (M^+) (Chart 3).

In conclusion, the first syntheses of heterocycle[*g,h*]-condensed-purines **2b** and **2c** have been first achieved by intramolecular cyclization of **6b, c** using HMDS in the presence of ammonium sulfate or trimethylchlorosilane as a catalyst. Although the PDE 4-inhibitory activity of **2b** and **2c** were evaluated, along with **1** and XT-44²⁾ *in vitro*, according

Table 1. PDE Inhibitory Activities of **2b** and **2c**

Compd. No	IC ₅₀ (μM)		
	PDE 1	PDE 3	PDE 4
2b	>100	>100	>100
2c	>100	>100	>100
1	—	>100	3.00
XT-44	—	>100	3.47

to the published methods,³⁾ **2b** and **2c** showed no inhibitory activity against PDE 1, PDE 3 or PDE 4 (Table 1). However, these results indicate that introduction of a heterocycle-ring to the [*i*]-position of purine is important to elicit PDE 4-inhibitory activity, although [*g,h*]-condensation removes the inhibitory activities against PDE 1 and PDE 3 isoenzymes.

Experimental

Melting points were measured on a Yanagimoto micro melting point hot stage apparatus and are uncorrected. IR spectra were determined with a Hitachi 270-30 spectrometer and MS were measured with a JEOL-DX300 instrument. ¹H-NMR was recorded on a JEOL-EX90A spectrometer. Chemical shifts are quoted in parts per million (ppm) with tetramethylsilane as an internal standard, and coupling constants (*J*) are given in hertz (Hz). Micro analyses were performed in the Micro analytical Laboratory of this faculty by Mrs. T. Kuroda. Yields and physicochemical data of the [7-(*N*-benzyloxycarbonyl)aminoalkyl]-3-propyl-purine-2,4-dione (**5**), 7-aminoalkyl-3-propyl-purine-2,4-dione (**6**) and the condensed-purines (**2b, c**) are summarized in Tables 2, 3, 4 and 5, respectively.

***N*-Benzyloxycarbonylaminoalkyl Methanesulfonate (4)** General Procedure: To a solution of *N*-benzyloxycarbonylaminoalkanol⁷⁾ (0.01 mol) in CH₂Cl₂ (30 ml) was added triethylamine (0.012 mol) and methanesulfonyl chloride (0.012 mol) with stirring at 0 °C. After the reaction mixture was stirred for 1 h at room temperature, water was added, and the mixture was extracted with AcOEt. The extracts were washed with brine, dried, and evaporated *in vacuo*. The residue was purified by silica gel column chromatography using hexane-AcOEt (3 : 1) as an eluent to give **4**.

Table 2. Physical Properties for Compounds **5** and **6**

Compd. No.	Yield (%)	mp (°C)	Recryst. solvent	Formula	Analysis (%)		
					Calcd	(Found)	
					C	H	N
5a	86	203—204	MeOH	C ₁₈ H ₂₁ N ₅ O ₄	58.21 (58.26)	5.70 (5.95)	18.86 (18.59)
5b	68	195—196	MeOH	C ₁₉ H ₂₃ N ₅ O ₄	59.21 (59.19)	6.01 (5.95)	18.17 (18.01)
5c	70	135—136	MeOH	C ₂₀ H ₂₅ N ₅ O ₄	60.14 (60.41)	6.31 (6.31)	17.53 (17.30)
6a	83	174—175	MeOH–AcOEt	C ₁₀ H ₁₅ N ₅ O ₂	50.61 (50.40)	6.40 (6.15)	29.51 (29.29)
6b	95	129—130	MeOH–AcOEt	C ₁₁ H ₁₇ N ₅ O ₂	52.58 (52.83)	6.82 (6.55)	27.89 (27.68)
6c	99	130—131	MeOH–AcOEt	C ₁₂ H ₁₉ N ₅ O ₂	54.32 (54.22)	7.22 (7.02)	26.40 (26.23)

Table 3. Spectral Data for Compound **5** and **6**

Compd. No.	IR (KBr) cm ⁻¹	¹ H-NMR
5a^a	3352, 1714, 1684	0.86 (3H, t, <i>J</i> =7.2 Hz), 1.65 (2H, sext., <i>J</i> =7.2 Hz), 3.40—3.52 (2H, m), 3.87 (2H, t, <i>J</i> =7.2 Hz), 4.26 (2H, t, <i>J</i> =5.5 Hz), 4.96 (2H, s), 7.31 (5H, s), 7.88 (1H, s), 11.10 (1H, br s)
5b^b	3408, 1694	0.98 (3H, t, <i>J</i> =7.2 Hz), 1.71 (2H, sext., <i>J</i> =7.2 Hz), 2.05 (2H, quint., <i>J</i> =6.2 Hz), 3.19 (2H, t, <i>J</i> =6.2 Hz), 4.02 (2H, t, <i>J</i> =7.2 Hz), 4.31 (2H, t, <i>J</i> =6.2 Hz), 5.12 (2H, s), 7.35 (5H, s), 7.64 (1H, s), 7.89 (1H, br s)
5c^b	3348, 1714, 1688	0.98 (3H, t, <i>J</i> =7.3 Hz), 1.55—2.01 (6H, m), 3.22 (2H, t, <i>J</i> =6.2 Hz), 4.03 (2H, t, <i>J</i> =7.3 Hz), 4.25 (2H, t, <i>J</i> =6.2 Hz), 5.09 (2H, s), 7.33 (5H, s), 7.57 (1H, s), 8.76 (1H, br s)
6a^a	3356, 1694	0.87 (3H, t, <i>J</i> =7.3 Hz), 1.66 (2H, sext., <i>J</i> =7.3 Hz), 2.89 (2H, t, <i>J</i> =6.0 Hz), 3.44 (2H, br s), 3.87 (2H, t, <i>J</i> =7.3 Hz), 4.16 (2H, t, <i>J</i> =6.0 Hz), 7.97 (1H, s)
6b^c	3360, 1700	0.95 (3H, t, <i>J</i> =7.4 Hz), 1.76 (2H, sext., <i>J</i> =7.4 Hz), 2.05, (2H, quint., <i>J</i> =7.0 Hz), 3.99 (2H, t, <i>J</i> =7.4 Hz), 4.38 (2H, <i>J</i> =7.0 Hz), 7.96 (1H, s)
6c^b	3464, 1698, 1620	0.97 (3H, t, <i>J</i> =7.3 Hz), 1.45—2.13 (6H, m), 2.82 (2H, t, <i>J</i> =6.7 Hz), 4.02 (2H, t, <i>J</i> =7.3 Hz), 4.28 (2H, t, <i>J</i> =6.7 Hz), 7.59 (1H, s), 8.53 (1H, br s)

NMR spectra were recorded in a) DMSO-*d*₆; b) CDCl₃ and c) CD₃OD.Table 4. Physical Properties for [g,h]Condensed-Purines **2b**, **c** and **11**

Compd. No.	Catalyst	Yield (%)	mp (°C) (recryst. solvent)	Formula	Analysis (%)		
					Calcd	(Found)	
					C	H	N
2b	(NH ₄) ₂ SO ₄	70	282—283 (AcOEt–MeOH)	C ₁₁ H ₁₅ N ₅ O	56.63 (56.83)	6.48 (6.56)	30.02 (30.12)
2c	TMS–Cl	46	273—274 (AcOEt–MeOH)	C ₁₂ H ₁₇ N ₅ O	58.28 (58.19)	6.69 (6.73)	28.32 (28.23)
11	(NH ₄) ₂ SO ₄	34	>290 (MeOH–H ₂ O)	C ₂₀ H ₂₆ N ₁₀ O ₂	54.78 (54.50)	5.98 (6.07)	31.94 (31.88)

Table 5. Spectral Data for [g,h]Condensed-Purines **2b**, **c** and **11**

Compd. No.	MS (<i>m/z</i>)	IR (KBr) cm ⁻¹	¹ H-NMR (DMSO- <i>d</i> ₆)
2b	233 (M ⁺)	3452, 1638	0.98 (3H, t, <i>J</i> =7.5 Hz), 1.81 (2H, sext., <i>J</i> =7.5 Hz), 2.30 (2H, quint., <i>J</i> =5.3 Hz), 3.94 (2H, t, <i>J</i> =5.3 Hz), 4.07 (2H, t, <i>J</i> =7.5 Hz), 4.31 (2H, t, <i>J</i> =5.3 Hz), 7.64 (1H, s), 10.57 (1H, br s)
2c^a	247 (M ⁺)	3456, 1698, 1620	0.97 (3H, t, <i>J</i> =7.4 Hz), 1.60—2.15 (6H, m), 3.74 (2H, t, <i>J</i> =5.6 Hz), 4.07 (2H, t, <i>J</i> =7.4 Hz), 4.28 (2H, t, <i>J</i> =5.6 Hz), 7.59 (1H, s), 9.82 (1H, br s)
11	438 (M ⁺)	3436, 1676, 1614	0.79 (6H, t, <i>J</i> =7.5 Hz), 1.54 (4H, sext., <i>J</i> =7.3 Hz), 3.76 (4H, t, <i>J</i> =7.5 Hz), 4.48—4.67 (4H, m), 8.31 (2H, s)

a) NMR spectrum was recorded in CDCl₃.

4a: Yield: 90%; HR-MS m/z : 273.0761 (Calcd for $C_{11}H_{15}NO_5S$: 273.0761). 1H -NMR ($CDCl_3$) δ : 2.99 (3H, s), 3.57 (2H, t, $J=5.2$ Hz), 4.30 (2H, t, $J=5.2$ Hz), 4.72 (2H, s), 5.24 (1H, br s), 7.35 (5H, s). IR (KBr) cm^{-1} : 3408, 1718.

4b: Yield: 92%; HR-MS m/z : 287.0821 (Calcd for $C_{12}H_{17}NO_5S$: 287.0821). 1H -NMR ($CDCl_3$) δ : 1.95 (2H, quint., $J=6.0$ Hz), 2.99 (3H, s), 3.13–3.36 (2H, m), 4.28 (2H, t, $J=6.0$ Hz), 5.10 (2H, s), 5.24 (1H, br s), 7.35 (5H, s). IR (KBr) cm^{-1} : 3424, 1712.

4c: Yield: 90%; HR-MS m/z : 301.0985 (Calcd for $C_{13}H_{19}NO_5S$: 301.0984). 1H -NMR ($CDCl_3$) δ : 1.64–1.86 (4H, m), 3.00 (3H, s), 3.24 (2H, t, $J=6.1$ Hz), 4.24 (2H, t, $J=6.1$ Hz), 4.68 (1H, br s), 5.10 (1H, s), 7.35 (5H, s). IR (KBr) cm^{-1} : 3416, 1714.

[7-(*N*-Benzyloxycarbonyl)aminoalkyl]-3-propylpurine-2,4-dione (5)
General Procedure: To a mixture of enprofylline **3** (15.5 mmol) and anhydrous K_2CO_3 (18.6 mmol) in dimethylformamide (DMF) (60 ml) was added (*N*-benzyloxycarbonyl)aminoalkyl methanesulfonate **4** (18.6 mmol) at 0 °C, the mixture was stirred at room temperature overnight, then concentrated *in vacuo*. The residue was chromatographed on silica gel using $CHCl_3$ -MeOH (15 : 1) as an eluent to give **5**.

7-Aminoalkyl-3-propylpurine-2,4-dione (6) General Procedure: To a solution of **5** (8 mmol) in MeOH (200 ml) was added 20% palladium hydroxide on carbon (30 mg), and the mixture was shaken under hydrogen (3 atm) for 2 h. The catalyst was removed and the filtrate concentrated *in vacuo*, and the residue crystallized to yield **6**.

Formation of Condensed-Purine (2b,c) General Procedure: To a solution of **6** (2 mmol) and HMDS (1.29 g, 8 mmol) in pyridine (15 ml) was added $(NH_4)_2SO_4$ (50 mg) or trimethylchlorosilane (2 mmol) and the mixture was stirred at 140 °C for 24 h. After cooling and addition of MeOH (20 ml), the reaction mixture was stirred at room temperature for 15 min and concentrated *in vacuo*. The residue was chromatographed on silica gel using $CHCl_3$ -MeOH (4 : 1) as an eluent to give **2b, c**.

References

- 1) Genain C. P., Roberts T., Davis R. T., Nguyen M. H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S. L., *Proc. Natl. Acad. Sci. U.S.A.*, **92**, 3601–3605 (1995); Nicholson C. D., Shahid M., *Pulmonary Pharmacol.*, **7**, 1–17 (1994); Palfreyman M. N., Souness J. E., *Prog. Med. Chem.*, **33**, 1–52 (1996); Sekut L., Yarnall D., Simpson S. A., Noel L. S., Batemanfite R., Clark R. L., Brackeen M. F., Menius J. A., Connolly K. M., *Clin. Exp. Immunol.*, **100**, 126–132 (1995); Sommer N., Loschmann P. A., Northoff G. H., Weller M., Steinbrecher A., Steinbach J. P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R., *Nat. Med.*, **1**, 244–248 (1995).
- 2) Miyamoto K., Kurita M., Ohmae S., Sakai R., Sanae F., Takagi K., *Eur. Pharmacol. (Mol. Pharmacol. Soc.)*, **267**, 317–322 (1994); Miyamoto K., Sakai R., Kurita M., Ohmae S., Sanae F., Sawanishi H., Hasegawa T., Takagi K., *Biol. Pharm. Bull.*, **18**, 431–434 (1995).
- 3) Sawanishi H., Suzuki H., Yamamoto S., Waki Y., Kasugai S., Ohya K., Suzuki N., Miyamoto K., Takagi K., *J. Med. Chem.*, **40**, 3248–3253 (1997).
- 4) Glushkov R. G., Ovcharova I. M., Muratov M. A., Kaminka M. E., Mashkovskii M. P., *Khim. Farm. Zh.*, **11**, 30–35 (1977).
- 5) Cottam H. B., Shih H., Tehrani L. R., Wasson D. B., Carson D. A., *J. Med. Chem.*, **39**, 2–9 (1996).
- 6) Vorbruggen H., Krolkiewicz K., *Chem. Ber.*, **117**, 1523–1541 (1984); *Idem*, *Justus Liebigs Ann. Chem.*, **1976**, 745–761.
- 7) Rose W. G., *J. Am. Chem. Soc.*, **69**, 1384–1388 (1947); Fernand Schneider, Karl Bernauer, Guggisberg A., van den Broek P., Hesse M., Schmid H., *Helv. Chem. Acta*, **57**, 434–440 (1974); Muramatsu M., Hayakumo Y., Fujii S., *J. Biochem.*, **62**, 408–418 (1967).